{"paper_id": "00de7e43d12ce08306c79245e9b6ced401c1e4e4", "metadata": {"title": "Clinical Update in COVID-19 \u2026", "authors": [{"first": "S", "middle": [], "last": "Chatterjee", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Remdesivir", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": "Since the outbreak of COVID 19 , there has been extensive attempt from every sphere to come up with a suitable medicine for treatment purpose. However, till date there has been no single approved medicine for COVID 19 treatment [1] though several of them are in clinical trial and are showing promising result. Remdesivir is presently the frontrunners among the drug of choice for the treatment of COVID-19 as evidenced from clinical trials. However, there is no consolidated critical clinical summery on the activity and performance of Remdesivir in clinical settings. This article approaches a critical appreciation on the drug based on clinical evidences which is essential in present context. of suspect and laboratory confirmed COVID 19 case in adult and children hospitalized with severe disease [7] . The EPA allows Remdesivir to be distributed and administered intravenously by health care providers, as appropriate for the treatment of COVID-19. Based on the evaluation of EUA and clinical evidence available, considering the non-availability of any drug or treatment options for COVID-19, Remdesivir is assumed to be effective. The fact sheet provides detailed guidelines in this regard. EUA is provided to Gilead Sciences Inc. that simultaneously carries out clinical trials. ", "cite_spans": [{"start": 28, "end": 30, "text": "19", "ref_id": "BIBREF16"}, {"start": 228, "end": 231, "text": "[1]", "ref_id": "BIBREF0"}, {"start": 802, "end": 805, "text": "[7]", "ref_id": "BIBREF6"}], "ref_spans": [], "section": "Introduction"}, {"text": "Remdesivir is a prodrug of an adenosine triphosphate (ATP) analog and its triphosphate form (RDV-TP) is known to inhibit the synthesis of viral RNA by delayed chain termination method [5] . A probable molecular mechanism is deciphered that the RDT-TP binds with RNA dependent RNA Polymerase [6] and forms complex with the viral RNA and ATP to inhibit RNA synthesis [9] . \u25b6Fig 2 summarizes the plausible mechanism of Remdesivir.", "cite_spans": [{"start": 184, "end": 187, "text": "[5]", "ref_id": "BIBREF4"}, {"start": 291, "end": 294, "text": "[6]", "ref_id": "BIBREF5"}, {"start": 365, "end": 368, "text": "[9]", "ref_id": "BIBREF7"}], "ref_spans": [], "section": "Probable mechanism against COVID19"}, {"text": "The USFDA through EUA suggests the use of Remdesivir, administered through intravenous (IV) infusion to treat COVID 19. Though the optimal dose and duration of treatment remains unknown, their suggestion is depicted in \u25b6table 1 [10] .", "cite_spans": [{"start": 228, "end": 232, "text": "[10]", "ref_id": "BIBREF8"}], "ref_spans": [], "section": "Dosage and use"}, {"text": "It is advisable to use Remdesivir during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus. Since the pharmacokinetic analysis of Remdesivir is unavailable for patient with renal as well as hepatic imparement, its use is subject to potential risk and benefit consideration i. e. when the potential benefit outweighs the potential risk. Hepatic laboratory testing is compulsory during treatment [10] .", "cite_spans": [{"start": 442, "end": 446, "text": "[10]", "ref_id": "BIBREF8"}], "ref_spans": [], "section": "Other considerations and possible side effect"}, {"text": "Several infusions related reactions and symptoms including hypotension, nausea, vomiting, diaphoresis etc. are also reported in some case, that might require discontinuing the drug if clinically significant reaction takes place. Alanine aminotransferase (ALT) \u25b6Fig. 1 Chemical Structure of Remdesivir.", "cite_spans": [], "ref_spans": [], "section": "Other considerations and possible side effect"}, {"text": "\u25b6Fig. 2 Plausible mechanism of action of Remdesivir against COVID19. elevation is also seen [10] . The most common adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. In general, adverse events were more common in patients receiving invasive ventilation [11] .", "cite_spans": [{"start": 92, "end": 96, "text": "[10]", "ref_id": "BIBREF8"}, {"start": 300, "end": 304, "text": "[11]", "ref_id": "BIBREF9"}], "ref_spans": [], "section": "Other considerations and possible side effect"}, {"text": "The empirical non-clinical data of side-effect of Remdesivir is limited to mostly in-vitro observations. However, in-vivo pharmacological studies showed that Remdesivir may transiently increase respiratory rate while no significant effect on respiration or EKG have been recorded. Remdesivir is also negative in genotoxicity studies. No renal or hepatic abnormalities were attributed to Remdesivir usage [12] . No effect on CNS and cardiovascular function have been reported [13] . Considering these facts, Remdesivir is still not beyond question [14] and remains incompletely defined in human population [15] .", "cite_spans": [{"start": 404, "end": 408, "text": "[12]", "ref_id": null}, {"start": 475, "end": 479, "text": "[13]", "ref_id": "BIBREF10"}, {"start": 547, "end": 551, "text": "[14]", "ref_id": "BIBREF12"}, {"start": 605, "end": 609, "text": "[15]", "ref_id": "BIBREF13"}], "ref_spans": [], "section": "Other considerations and possible side effect"}, {"text": "The process of systemic review was followed (\u25b6 Figure 3) Feb 2020, that has peaked up since the declaration of pandemic by WHO on 12 th March 2020. Analyzing the clinical trials from \u25b6table 2 it is evident that there is attempt to use Remdesivir alone or in combination with other drugs for the treatment of COVID 19. The non-availability of any suitable drug for the therapeutic purpose of COVID 19 as well as lack of information regarding safety issue of Remdesivir has promted its use only in hospital set-up and that too for critically ill patents. Data of adverse drug effect and long term use are expected only by the end of this year through several studies. Only a mere handful of publications are reported from the results of clinical trials (17, 18) while most of them are yet to be completed and still inconclusive. As a result, Remdesivir still remains as investigational drug, distant from USFDA approval.", "cite_spans": [{"start": 751, "end": 755, "text": "(17,", "ref_id": "BIBREF14"}, {"start": 756, "end": 759, "text": "18)", "ref_id": "BIBREF15"}], "ref_spans": [{"start": 47, "end": 56, "text": "Figure 3)", "ref_id": null}], "section": "Clinical research output"}, {"text": "There has been 660 Scientific publications found on the keyword 'Remdesivir; in pubmed.gov. out of which 636 are from the current year. However, a majority of them are review articles and meta-analysis while only 7 reflect results of clinical trials. The following \u25b6table 3 summarizes the clinical results reflected in research publication.", "cite_spans": [], "ref_spans": [], "section": "Scientific Publications"}, {"text": "Remdesivir is presently a 'molecule of hope' to the world to stop the menace of COVID19. However, it has to cross stringent safety regulations and clinical trial to be out of question. It is to be remembered that Remdesivir is still not a USFDA approved drug and its efficacy against COVID 19 are initial result that requires subsequent validation and safety/ risk analysis studies for a longer duration to act as a full proof weapon against COVID 19. Careful monitoring of patient condition and parameters are warranted during Remdesivir administration. Scientific research should also look beyond this molecule to come up with better alternatives, which remains a challenge considering present situation. In this trial ethical and moral obligation of patients are evaluated in terms of effective treatment. The trial is a reproduction of Remdesivir and other drug usage to identify whether the drugs offer real time benefit to patients.", "cite_spans": [], "ref_spans": [], "section": "Conclusion"}, {"text": "[24]", "cite_spans": [], "ref_spans": [], "section": "Conclusion"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Division of Viral Diseases. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "The Story of Remdesivir", "authors": [{"first": "Bret", "middle": [], "last": "Stephens", "suffix": ""}], "year": 2020, "venue": "The New York Times. p. A23. Retrieved", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys", "authors": [{"first": "T", "middle": ["K"], "last": "Warren", "suffix": ""}, {"first": "R", "middle": [], "last": "Jordan", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Lo", "suffix": ""}], "year": 2016, "venue": "Nature", "volume": "531", "issn": "", "pages": "381--385", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency", "authors": [{"first": "C", "middle": ["J"], "last": "Gordon", "suffix": ""}, {"first": "E", "middle": ["P"], "last": "Tchesnokov", "suffix": ""}, {"first": "E", "middle": [], "last": "Woolner", "suffix": ""}], "year": 2020, "venue": "J Biol Chem", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1074/jbc.RA120.013679"]}}, "BIBREF5": {"ref_id": "b5", "title": "Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease", "authors": [{"first": "M", "middle": ["L"], "last": "Agostini", "suffix": ""}, {"first": "E", "middle": ["L"], "last": "Andres", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Sims", "suffix": ""}], "year": 2018, "venue": "MBio", "volume": "9", "issn": "", "pages": "221--00218", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment", "authors": [{"first": "", "middle": [], "last": "Coronavirus", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More. Archives of Medical research", "authors": [{"first": "A", "middle": [], "last": "Saha", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Sharma", "suffix": ""}, {"first": "M", "middle": [], "last": "Bhattacharya", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.arcmed.2020.05.001"]}}, "BIBREF8": {"ref_id": "b8", "title": "USFDA Fact Sheet For Health Care Providers", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Compassionate Use of Remdesivir for Patients with Severe Covid-19", "authors": [{"first": "J", "middle": [], "last": "Grein", "suffix": ""}, {"first": "N", "middle": [], "last": "Ohmagari", "suffix": ""}, {"first": "D", "middle": [], "last": "Shin", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "382", "issn": "", "pages": "2327--2336", "other_ids": {"DOI": ["10.1056/NEJMoa2007016"]}}, "BIBREF10": {"ref_id": "b10", "title": "An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease", "authors": [{"first": "D", "middle": [], "last": "Javorac", "suffix": ""}, {"first": "L", "middle": [], "last": "Grahovac", "suffix": ""}, {"first": "L", "middle": [], "last": "Mani\u0107", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Status of Remdesivir: Not Yet Beyond Question!", "authors": [{"first": "S", "middle": [], "last": "Chatterjee", "suffix": ""}], "year": 2020, "venue": "Arch Med Res", "volume": "", "issn": "", "pages": "", "other_ids": {"PMID": ["32972773"]}}, "BIBREF13": {"ref_id": "b13", "title": "Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature", "authors": [{"first": "A", "middle": [], "last": "Musa", "suffix": ""}, {"first": "K", "middle": [], "last": "Pendi", "suffix": ""}, {"first": "A", "middle": [], "last": "Hashemi", "suffix": ""}], "year": 2020, "venue": "West J Emerg Med", "volume": "21", "issn": "", "pages": "737--741", "other_ids": {"DOI": ["10.5811/west-jem.2020.5.47658"]}}, "BIBREF14": {"ref_id": "b14", "title": "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial", "authors": [{"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "D", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "G", "middle": [], "last": "Du", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "", "issn": "", "pages": "31022--31031", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Controlled Trial of Ebola Virus Disease Therapeutics", "authors": [{"first": "S", "middle": [], "last": "Mulangu", "suffix": ""}, {"first": "L", "middle": ["E"], "last": "Dodd", "suffix": ""}, {"first": "R", "middle": ["T"], "last": "Davey", "suffix": ""}], "year": 2019, "venue": "N Engl J Med", "volume": "", "issn": "", "pages": "2293--2303", "other_ids": {"DOI": ["10.1056/NEJMoa1910993"]}}, "BIBREF16": {"ref_id": "b16", "title": "Remdesivir for the Treatment of Covid-19 -Preliminary Report", "authors": [{"first": "J", "middle": ["H"], "last": "Beigel", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Tomashek", "suffix": ""}, {"first": "L", "middle": ["E"], "last": "Dodd", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Randomised controlled trial begins for Ebola therapeutics", "authors": [{"first": "E", "middle": [], "last": "Nakkazi", "suffix": ""}], "year": null, "venue": "Lancet", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/S0140-6736(18)33011-3PMID:30527603"]}}, "BIBREF19": {"ref_id": "b19", "title": "Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status", "authors": [{"first": "S", "middle": [], "last": "Antinori", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Cossu", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Ridolfo", "suffix": ""}], "year": 2020, "venue": "Pharmacol Res", "volume": "158", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.phrs.2020.104899"], "PMID": ["32407959"]}}, "BIBREF20": {"ref_id": "b20", "title": "Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects", "authors": [{"first": "R", "middle": [], "last": "Humeniuk", "suffix": ""}, {"first": "A", "middle": [], "last": "Mathias", "suffix": ""}, {"first": "H", "middle": [], "last": "Cao", "suffix": ""}], "year": 2020, "venue": "Clin Transl Sci", "volume": "13", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1111/cts.12840"], "PMID": ["32589775"]}}, "BIBREF21": {"ref_id": "b21", "title": "GS-US-540-5774 Investigators. Effect of Remdesivir vs. Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial", "authors": [{"first": "C", "middle": ["D"], "last": "Spinner", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Gottlieb", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Criner", "suffix": ""}], "year": 2020, "venue": "JAMA", "volume": "324", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1001/jama.2020.16349"], "PMID": ["32821939"]}}, "BIBREF22": {"ref_id": "b22", "title": "Respuestas r\u00e1pidas a la pandemia de COVID-19 a trav\u00e9s de la ciencia y la colaboraci\u00f3n global: el ensayo cl\u00ednico Solidaridad", "authors": [{"first": "A", "middle": [], "last": "Soto", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Qui\u00f1ones-Laveriano", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Garcia", "suffix": ""}], "year": 2020, "venue": "Rev Peru Med Exp Salud Publica", "volume": "37", "issn": "", "pages": "356--360", "other_ids": {"DOI": ["10.17843/rpmesp.2020.372.5546"], "PMID": ["32876229"]}}}, "ref_entries": {"TABREF0": {"text": "to analyze the recent developments of Remdesivir in clinical studies from NIH: US National Library of Medicine [16]. At present (till Sep 2020) 30 clinical studies could be traced involving Remdesivir (Refer \u25b6 table 2) from the NIH, US National Library of Medicine Clinical Trial Registry (ClinicalTrials.gov) out of which 25 are of interventional type, 3 are observational and rest 2 are Expanded access type. Most of the clinical trials are in stage II and stage III (22 out of 30) indicating promising initial results yet require more time for validation and declared to be safe. Most of the trials are presently in recruiting stage while a mere 1-2 studies have been concluded. Medicinal intervention to treat COVID 19 by the process of drug repurposing as well as novel antiviral candidates could be found from \u25b6table 1 Dose of Remdsivir suggested by USFDA [7]. Details of Clinical Trials on Remdesvir for therapeutic application against virus (especially COVID19). Details of Clinical Trials on Remdesvir for therapeutic application against virus (especially COVID19). Details of Clinical Trials on Remdesvir for therapeutic application against virus (especially COVID19). Details of Clinical Trials on Remdesvir for therapeutic application against virus (especially COVID19).", "latex": null, "type": "table"}, "TABREF1": {"text": "List of Publications depicting results of clinical trials on Remdesivir (Source: pubmed.gov).This study of adult patients admitted to hospital for severe COVID-19 showed thatremdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies were addressed through a randomized, controlled trial. A trial of 681 patients was conducted that showed both MAb114 and REGN-EB3 were superior to ZMapp and Remdesivir in reducing mortality from EVD.A trial to assess the efficacy of investigational therapeutics against Ebola virus disease has been launched in DR Congo. The trial is designed to test the safety, efficacy, and feasibility of investigational therapeutics(Remdesivir) against Ebola virus disease This prospective (compassionate), open-label study of remdesivir, which was conducted that showed remdesivir can benefit patients with SARS-CoV-2 pneumonia hospitalised outside ICU where clinical outcome was better and adverse events are less frequently observed. Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects Remdesivir exhibited favorable safety and PK profiles that supported once-daily dosing. Effect of Remdesivir vs. Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial Randomised control trial was conducted on 596 patients with moderate COVID-19. 10 day course of Remdesivir did not show statistically significant difference in clinical status compared with standard care while patient randomised to 5 day course showed statistically significant difference in clinical status compared with standard care. However the difference was uncertain clinical importance. Respuestas r\u00e1pidas a la pandemia de COVID-19 a trav\u00e9s de la ciencia y la colaboraci\u00f3n global: el ensayo cl\u00ednico Solidaridad. [Article in Spanish]", "latex": null, "type": "table"}}, "back_matter": [{"text": "The author declares that there is no conflict of interest.", "cite_spans": [], "ref_spans": [], "section": "Conflict of Interest"}]}